PROCEPT BioRobotics Corp (PRCT)
Data as of , from SEC Form 4 filings.
See up to 3 months of PRCT. The 7-day demo opens the 1M and 3M ranges and puts PRCT on your watchlist.
Start 7-day demoLatest PRCT insider trades
- Alaleh Nouri - OfficerOpen-market sale$6K
Barry L. Templin
About PROCEPT BioRobotics Corp (PRCT)
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
- SAN JOSE, CA
- 888
- 2021
- Nasdaq
https://www.procept-biorobotics.comSEC filings for PRCT on EDGAR
PRCT Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 1 | 23,900 | $498K |
| Open-market sale | 3 | 1,043 | $22K |
| Grant or award | 10 | 263,895 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
PRCT insider transactions (Form 4)
5844 Form 4 filings on record, the earliest from Oct 17, 2024, newest first. Filing history page 2 of 2.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Larry L. Wood - Officer | Grant or award | Common Stock | 182,392 | $0.00 | - | |
| Larry L. Wood - Officer | Grant or award | Stock Option (Right to Buy) | 319,618 | $0.00 | - | |
| Frederic H. Moll - Director | Open-market purchase | Common Stock | 20,000 | $39.26 | $785K | |
| Antal Rohit Desai - Director | Option exercise | Common Stock | 26,749 | $1.33 | $36K | |
| Antal Rohit Desai - Director | Option exercise | Stock Option (Right to Buy) | 26,749 | $0.00 | - | |
| Alaleh Nouri - Officer | Option exercise | Common Stock | 11,000 | $4.52 | $50K | |
| Alaleh Nouri - Officer | Option exercise | Stock Option (Right to Buy) | 11,000 | $0.00 | - | |
| Frederic H. Moll - Director | Grant or award | Common Stock | 1,538 | $0.00 | - | |
| Frederic H. Moll - Director | Grant or award | Stock Option (Right to Buy) | 2,771 | $0.00 | - | |
| Thomas M. Prescott - Director | Grant or award | Common Stock | 1,538 | $0.00 | - | |
| Thomas M. Prescott - Director | Grant or award | Stock Option (Right to Buy) | 2,771 | $0.00 | - | |
| Reza Zadno - Officer | Open-market sale | Common Stock | 5,300 | $96.15 | $510K | |
| Reza Zadno - Officer | Open-market sale | Common Stock | 13,762 | $97.01 | $1.34M | |
| Reza Zadno - Officer | Open-market sale | Common Stock | 5,126 | $98.09 | $503K | |
| Reza Zadno - Officer | Open-market sale | Common Stock | 2,235 | $99.04 | $221K | |
| Alaleh Nouri - Officer | Option exercise | Common Stock | 11,838 | $7.27 | $86K | |
| Alaleh Nouri - Officer | Option exercise | Common Stock | 4,162 | $34.99 | $146K | |
| Alaleh Nouri - Officer | Option exercise | Common Stock | 12,092 | $37.02 | $448K | |
| Alaleh Nouri - Officer | Open-market sale | Common Stock | 3,787 | $96.12 | $364K | |
| Alaleh Nouri - Officer | Open-market sale | Common Stock | 16,187 | $96.98 | $1.57M | |
| Alaleh Nouri - Officer | Open-market sale | Common Stock | 8,118 | $97.90 | $795K | |
| Alaleh Nouri - Officer | Option exercise | Stock Option (Right to Buy) | 11,838 | $0.00 | - | |
| Alaleh Nouri - Officer | Option exercise | Stock Option (Right to Buy) | 4,162 | $0.00 | - | |
| Alaleh Nouri - Officer | Option exercise | Stock Option (Right to Buy) | 12,092 | $0.00 | - | |
| Reza Zadno - Officer | Open-market sale | Common Stock | 18,144 | $97.25 | $1.76M | |
| Reza Zadno - Officer | Open-market sale | Common Stock | 1,684 | $98.00 | $165K | |
| Reza Zadno - Officer | Open-market sale | Common Stock | 5,189 | $99.24 | $515K | |
| Reza Zadno - Officer | Open-market sale | Common Stock | 1,403 | $99.96 | $140K | |
| Reza Zadno - Officer | Open-market sale | Common Stock | 10,111 | $92.12 | $931K | |
| Reza Zadno - Officer | Open-market sale | Common Stock | 15,809 | $92.82 | $1.47M | |
| Reza Zadno - Officer | Open-market sale | Common Stock | 500 | $93.88 | $47K | |
| Reza Zadno - Officer | Open-market sale | Common Stock | 10,509 | $92.74 | $975K | |
| Reza Zadno - Officer | Open-market sale | Common Stock | 2,000 | $93.64 | $187K | |
| Reza Zadno - Officer | Open-market sale | Common Stock | 9,401 | $94.95 | $893K | |
| Reza Zadno - Officer | Open-market sale | Common Stock | 4,510 | $95.58 | $431K | |
| Antal Rohit Desai - Director | Other | Common Stock | 660,302 | $0.00 | - | |
| Antal Rohit Desai - Director | Other | Common Stock | 172,016 | $0.00 | - | |
| Antal Rohit Desai - Director | Other | Common Stock | 62,944 | $0.00 | - | |
| Antal Rohit Desai - Director | Open-market sale | Common Stock | 7,566 | $95.38 | $722K | |
| Antal Rohit Desai - Director | Open-market sale | Common Stock | 11,756 | $96.49 | $1.13M | |
| Antal Rohit Desai - Director | Open-market sale | Common Stock | 11,487 | $97.17 | $1.12M | |
| Antal Rohit Desai - Director | Open-market sale | Common Stock | 2,191 | $98.43 | $216K | |
| Antal Rohit Desai - Director | Open-market sale | Common Stock | 9,403 | $95.68 | $900K | |
| Antal Rohit Desai - Director | Open-market sale | Common Stock | 2,678 | $96.57 | $259K | |
| Antal Rohit Desai - Director | Open-market sale | Common Stock | 17,150 | $97.59 | $1.67M | |
| Antal Rohit Desai - Director | Open-market sale | Common Stock | 3,769 | $98.29 | $370K | |
| Antal Rohit Desai - Director | Open-market sale | Common Stock | 6,992 | $94.42 | $660K | |
| Antal Rohit Desai - Director | Open-market sale | Common Stock | 16,272 | $95.33 | $1.55M | |
| Antal Rohit Desai - Director | Open-market sale | Common Stock | 10,236 | $96.03 | $983K | |
| Antal Rohit Desai - Director | Open-market sale | Common Stock | 500 | $97.54 | $49K | |
| Reza Zadno - Officer | Option exercise | Common Stock | 288,461 | $4.37 | $1.26M | |
| Reza Zadno - Officer | Open-market sale | Common Stock | 288,461 | $91.00 | $26.25M | |
| Reza Zadno - Officer | Option exercise | Stock Option (Right to Buy) | 288,461 | $0.00 | - | |
| Kevin Waters - Officer | Option exercise | Common Stock | 25,000 | $4.56 | $114K | |
| Kevin Waters - Officer | Open-market sale | Common Stock | 15,959 | $72.11 | $1.15M | |
| Kevin Waters - Officer | Open-market sale | Common Stock | 8,115 | $73.02 | $593K | |
| Kevin Waters - Officer | Open-market sale | Common Stock | 926 | $73.75 | $68K | |
| Kevin Waters - Officer | Option exercise | Stock Option (Right to Buy) | 25,000 | $0.00 | - |
Recent PRCT Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Kevin Waters | Officer | 373 | $8K | View on EDGAR | |
| Barry L. Templin | Officer | 373 | $8K |
PRCT insider trading FAQ
What is the latest insider trade for PRCT?
PROCEPT BioRobotics Corp (PRCT) had 9 insider filings in the last 90 days, with the most recent on 5 October 2026. The full record for PRCT runs to 44 Form 4 filings, the earliest from 17 October 2024. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying PRCT stock?
1 insider purchase of PRCT was filed in the last 90 days, totaling $498K.
How many insiders are selling PRCT stock?
3 insider sales of PRCT were filed in the last 90 days, totaling $22K.
Where can I see PRCT SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects PRCT Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Michael Mack view on EDGAR
- - Alaleh Nouri view on EDGAR
- - Barry L. Templin view on EDGAR
- - Kevin Waters view on EDGAR
- - Alaleh Nouri view on EDGAR
- - Barry L. Templin view on EDGAR
- - Kevin Waters view on EDGAR
- - Pooja Sharma view on EDGAR
- - Larry L. Wood view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where PRCT's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow PRCT with a 7-day demo
- PRCT on your watchlist
- Every PRCT Form 4 filing on record
- Up to 3 months of PRCT price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
